31% growth, margin lag; guided conservatively despite beat
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Beat revenue growth guidance (31% vs 20–25% range) but guided conservatively for full-year. EBITDA margin slight shortfall vs range; capex and capacity timelines credible.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Gala delivered strong Q2 results (31% revenue growth, ₹100+ Cr order book) but maintained FY27 guidance (20–25%) rather than raising it—a cautious stance that suggests management sees execution risk ahead. While the electrolyzer opportunity (₹40–50 Cr potential 2–3y) and capacity expansion (Chennai Phase 1/2, Wada land) provide long-term catalysts, near-term margin recovery lags guidance (16.7% vs 17–19% target), and working capital remains elevated. Recommend Hold pending Q3 delivery on Chennai ramp-up.
₹93.7 Cr
Revenue · +31.3% YoY₹10.6 Cr
Reported PAT · +26.1% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue growth 31% YoY, driven by volume + new components + new customer
METDelivered 93.7 Cr, +31.3% YoY. Breakdown: 3 pillars ~10% each (organic, new components, new customer).
Order book grew 44% YoY, crossed INR100 Cr for first time
METManagement cited >₹100 Cr order book as major milestone; 44% YoY growth is substantive.
PAT up 26% YoY at INR11 Cr, margins 11.31%
OVERSTATEDDelivered ₹10.6 Cr (+26.1% YoY), margin 11.1%. Management overstated by ~4% on absolute PAT.
EBITDA margin 16.76%, targeting 17–19% going forward
METDelivered OPM 16.7%, aligned. Guidance 17–19% is maintained from prior, not raised.
Chennai Phase 1 targeting ₹15 Cr revenue from Q3 onward; Phase 2 live Q4 FY27
METTimeline & revenue run-rate credible given capex milestones; Phase 2 capacity INR50 Cr.
On track for 25% revenue growth this year
METQ2 delivered 31%. Guidance range 20–25% maintained; statement aligns with mid-point of range.
Earnings quality
What changed since the last call
Electrolyzer entry — first bulk order secured
NewReceived ₹2 Cr order H1 FY27; discussing with 2 more suppliers. Opens ₹100+ Cr customer potential over 2–3y.
EBITDA margin guidance maintained at 17–19%
NeutralPrior call same range; Q2 delivered 16.7%. Management confident in gradual recovery via mix, manpower leverage, Chennai ramp.
Order book milestone: >₹100 Cr (first time)
UpgradeQ2 book 44% YoY growth. Reflects 3-pillar strategy: organic growth, new components from existing customers, new Tier-1 OEMs.
Land acquisition Wada: 10 acres secured, 3–5 more sought
NewWada MOU signed June 2026; legal finalization ongoing. Next 3–5 acres for Q3/Q4 FY28 capacity. SIPCOT approvals pending.
FY27 revenue growth guidance: maintained 20–25%
NeutralPrior guidance same range. Q2 beat at +31.3%, but management kept range unchanged for full-year (prudent, given cyclicality & macro uncertainty).
The Q&A
Analysts pressed on capacity utilization, working capital, and near-term vs multi-year growth inflection. Management held firm: detailed on capacity ramp (Phase 1 ₹15 Cr, Phase 2 ₹50 Cr timelines), transparent on inventory build rationale (export goods in transit, 25% volume growth), candid on margin headwinds (manpower costs offset product mix gains). No evasion; minor hedges on land approvals and government timelines. Overall tone: constructive, not defensive.
Capacity expansion plan — Aditya Pal, MSA Capital Partners
AnsweredCurrent INR450 Cr. Phase 2 at Chennai (10,000 sq ft mezzanine) adds INR50 Cr by Q4 FY27. Wada: 10 acres signed June 2026, to develop phased over 2–3 years, 2–3 stages. FY28 capex INR40–45 Cr covers land & initial builds.
Revenue breakdown & volume growth — Divyansh Gupta, Latent PMS
PartialThree pillars ~10% each: (1) organic volume growth, (2) new components from existing customers, (3) new customer entry. Price negligible. At 270 days inventory annually, ~100 days in quarter. Export 36%, import content high → goods-in-transit are inventory.
Electrolyzer opportunity — Ahaan, Individual Investor
AnsweredReceived 1st bulk order June 2026; INR2 Cr sales FY27. Discussing 2 more companies for sample development. Total potential INR40–50 Cr over 2–3 years (railways, offshore wind, mining safety). Already in advanced discussions with 1 export, 1 global electrolyzer company.
EBITDA margin trajectory — Vidhi Gandhi, Individual Investor
AnsweredProduct mix improvement, manpower cost reduction via automation, other expenses down 2.2%. H1 FY27 saw forex benefit (no loss in H1 vs H1 FY26 loss). Targeting 17–19% via further mix + manpower leverage as Chennai scales. Impact 1.3% improvement Q2.
Wind sector demand & market share — Lakan Chhabra, Individual Investor
AnsweredWind demand flat, but Gala gaining share from 5–25% to 25–30% with existing suppliers. Also: new product (bolt) approved; new markets (offshore, tower applications). Segment growing 25% YoY despite macro flatness; upside in offshore wind exports.
DSS capacity and utilization — Lakan Chhabra, follow-up
AnsweredAt 85% utilization currently. DSS + SFS capacity planned in new FY28 facility. Outsourcing options (machining, heat-treatment) also explored. Growth headroom available.
Working capital & KPMG optimization — Ahaan, Individual Investor
PartialKPMG completed diagnosis; report submitted. Will implement recommendations early FY28. 1–1.5 years to accrue benefits. Export receivables 90–100 days (industry standard). Working capital reduction of ~10% targeted further internally.
Chennai Phase 1 revenue ramp — Divyansh Gupta, follow-up
AnsweredPhase 1 capacity INR60 crores per annum. Phase 1 went live Aug 2025. Currently at 70% utilization on Phase 1 facility at Wada level. Phase 2 comes live Q4 FY27, adding INR50 Cr. Targeting INR15 Cr Chennai Phase 1 revenue from Q3 onward.
Capex and financing plan — Divyansh Gupta, multiple
PartialLand capex financed by accruals + internal funds (no term loan for land). Equipment capex (incremental at Wada/Chennai) may need INR40–45 Cr term loan in FY28, depending on cash position & order flow.
Solar power plant ROI — Hitesh Patel, Individual Investor
AnsweredCapex INR2.6 Cr; annual savings INR1.35 Cr (net of INR5 Cr term loan interest). Payback 4.5 years. Strategic: cost advantage + renewable export credential (CBAM compliance benefit).
Guidance
FY27 revenue growth 20–25% (maintained)
MediumQ2 beat at +31.3%, but guidance unchanged. Suggests management hedging for Q3/Q4 comps & macro uncertainty.
EBITDA margin 17–19% (maintained)
MediumQ2 at 16.76% (135 bps improvement YoY). Targeting further recovery via mix, manpower leverage, Chennai ramp. Headwinds: higher manpower cost for Europe/US expansion, forex volatility.
FY28 capex ₹40–45 Cr (new facility capex)
HighMajority for land acquisition Wada & Chennai Phase 2. Equipment capex for incremental capacity at existing sites. Financing via accruals + term loan (if required).
Risks the call surfaced
Execution risk: Capacity ramp
MediumChennai Phase 1 (₹15 Cr revenue target Q3) and Phase 2 (₹50 Cr capacity, Q4 FY27 launch) timelines are aggressive. Delays in commissioning or ramp-up would miss revenue & margin targets.
Land acquisition & approval delays
MediumWada 10-acre land MOU signed June 2026; legal finalization ongoing (draft agreement shared, some delays expected). Additional 3–5 acres for Q3–Q4 FY28 still in SIPCOT application stage (2 online filings pending).
Working capital intensity
MediumInventory & trade receivables grew sharply H1 due to 36% export mix (goods-in-transit = 90–100 DPO cycle) + 25% volume growth. OCF modest vs profitability. KPMG study on optimization ongoing; benefits 1–1.5 years away.
Electrolyzer customer concentration
MediumElectrolyzer order (₹2 Cr FY27) is from 1 global OEM. Upside ₹40–50 Cr over 2–3 years depends on 2 additional customers transitioning from sample to order. Market adoption of electrolyzer tech in India/global still nascent.
Export exposure & forex volatility
LowExport 36% of H1 revenue. H1 benefited from forex tailwind (no loss in H1 FY27 vs forex loss in H1 FY26). H2 currency movement could offset or enhance gains. New export markets (USA, Europe) scaling, so forex sensitivity will remain.
Management
Score 7/10. Direct, detailed on capacity plans & customer wins. Transparent on margin drivers (mix, manpower, forex). Minimal evasion; hedges appropriately on regulatory timelines & macro uncertainty. On track on major commitments: Chennai Phase 1 live (Aug 2025), Phase 2 Q4 FY27 confirmed. Order book >₹100 Cr validates demand. Q2 beat guidance (31% vs 20–25%), but maintained range rather than raising—prudent but also signals caution.
1 · Q3 FY27 (Oct–Dec 2026)
Chennai Phase 1 ramp-up to ₹15 Cr revenue run-rate
2 · Q4 FY27 (Jan–Mar 2027)
Chennai Phase 2 comes live; incremental ₹50 Cr capacity
3 · FY28 (Apr 2027+)
Electrolyzer orders scaled 2–3x (₹40–50 Cr potential); Wada expansion capex ₹40–45 Cr
Recommend Hold pending Q3 delivery on Chennai ramp-up.
Informational and educational content only. Not investment advice.